Idiopathic pulmonary fibrosis (IPF) is a challenging condition with an average survival rate of less than 3 years. Recent research has unveiled an intriguing connection between bacterial co-infection and IPF progression.
Pulmonary fibrosis is a severe lung condition characterized by scarring and thickening of lung tissue. As a result, your lungs become less efficient, making breathing more difficult. When the cause is unknown, it is classified as idiopathic.
Prevalence: About 59.7% of IPF patients have positive co-infections (both viral and bacterial).
Mortality Risk: Co-infected individuals have an eightfold higher risk of death than non-infected patients.
Co-infected patients have lower lung function and a higher risk of acute exacerbations.
Mechanisms Under Study:
Inflammation: Bacterial presence worsens lung inflammation, contributing to fibrosis progression.
Lung Microbiome: Alterations in the lung microbiome, including oral bacteria, play a pivotal role.
Treatment implications:
Understanding the impact of bacterial co-infection opens up new opportunities for targeted therapies. Researchers are looking into ways to modify the lung microbiome and improve patient outcomes.
References:
Moghoofei, M., Mostafaei, S., Kondori, N., Armstrong, M. E., & Babaei, F. (2022). Bacterial and viral coinfection in idiopathic pulmonary fibrosis patients: the prevalence and possible role in disease progression. BMC Pulmonary Medicine, 22, 60.
#microbiology
#researchscientist
#IPF
#Health
#bacterial
#viral